Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Renowned Analyst Maintains Positive Outlook for Mondaycom MNDY with Overweight Rating and 250 Price Target

Elaine Mendonca by Elaine Mendonca
February 5, 2024
in Breaking News
0
Technology Robotics Markets and money
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

On February 5, 2024, Brent Bracelin, a renowned analyst at Piper Sandler, expressed his unwavering confidence in Monday.com (MNDY) by reiterating an “overweight” rating and retaining a $250 price target for the company. This affirmation of the positive rating and price target signifies a promising outlook for the stock’s performance.

It is worth noting that Bracelin has consistently upheld this rating and price target in his recent reports, indicating a steadfast belief in the bright future prospects of Monday.com. With such unwavering support from an industry expert, investors can find reassurance in the company’s potential for growth and success.

MNDY Stock Performance: Mixed Results with Potential for Future Growth

On February 5, 2024, MNDY stock exhibited mixed performance, trading near the top of its 52-week range but experiencing a slight decrease in price. According to data from CNN Money, MNDY was trading above its 200-day simple moving average, indicating positive price momentum.

The price of MNDY shares decreased by $2.36 since the market last closed, representing a 1.10% drop. This decline suggests that investors may have been selling off their positions in the stock. However, it is worth noting that a 1.10% drop is relatively small and may not be indicative of a significant downward trend.

MNDY opened at $214.14, which was $0.08 higher than its previous close. This slight increase in the opening price could indicate some initial buying interest in the stock. However, it is important to consider the overall market conditions and other factors that may have influenced the stock’s performance throughout the day.

Trading near the top of its 52-week range suggests that MNDY has been performing well over the past year. This could be an encouraging sign for investors, as it indicates that the stock has been able to reach and maintain higher price levels. However, it is essential to conduct further analysis and consider other factors, such as company news and industry trends, to gain a comprehensive understanding of the stock’s potential future performance.

Investors should always exercise caution and conduct thorough research before making any investment decisions. Stock prices can be influenced by a multitude of factors, including market conditions, company financials, and investor sentiment. Therefore, it is crucial to consider a wide range of information and consult with a financial advisor if needed when evaluating the performance of a particular stock like MNDY.

Impressive Performance of MNDY Stock on February 5, 2024: Strong Revenue Growth and Improved Net Income

On February 5, 2024, MNDY stock demonstrated impressive performance, driven by its strong revenue growth and improved net income. MNDY reported a total revenue of $519.03 million for the past year, representing a remarkable increase of 68.43% compared to the previous year. Additionally, MNDY’s revenue increased by 7.69% compared to the previous quarter. The net income for MNDY over the past year was -$136.87 million, showing a decrease of 5.86% compared to the previous year. However, MNDY reported a net income of $7.49 million in Q3, reflecting a substantial increase of 206.44% compared to the previous quarter. MNDY’s earnings per share (EPS) also experienced positive growth, with an EPS of -$2.99 over the past year, showing a 34.08% increase compared to the previous year. The EPS for the most recent quarter, Q3, was $0.15, demonstrating an impressive increase of 205.76% compared to the previous quarter. Overall, MNDY’s stock performance on February 5, 2024, was driven by its strong revenue growth and improved net income.

Tags: MNDY
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Technology Artificial intelligence Market Capitalization

Thoma Bravo Acquires Everbridge Revolutionizing Critical Event Management Software

Real-estate-investing

Prominent REITs in the Multifamily Real Estate Market

Telecommunications Industry stock Trading

TMobile US Demonstrates Exceptional Market Performance and Growth Potential

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com